Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia
Although preclinical data are promising, there are many clinical challenges in developing CAR T-cell therapy in acute myeloid leukemia.
Ibrutinib in the Management of B-cell Malignancies
While ibrutinib is a relatively new option in the treatment of B-cell NHL, it has convincing antitumor activity as a single agent in a wide variety of B-cell lymphoma subtypes and is a viable therapeutic option for patients.